Veli Kairisto

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber et al. · The Lancet Oncology · 2018 · 587 citations · Full text

Hematological Malignancy, Medicine, Chronic Myeloid Leukaemia +10

The Nordic Reference Interval Project 2000: recommended reference intervals for 25 common biochemical properties

Pål Rustad, Peter Felding, Leifur Franzson et al. · Scandinavian Journal of Clinical and Laboratory Investigation · 2004 · 387 citations

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

Michele Baccarani, Gianantonio Rosti, Fausto Castagnetti et al. · Blood · 2009 · 196 citations

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Bengt Simonsson, Tobias Gedde‐Dahl, Berit Markevärn et al. · Blood · 2011 · 194 citations · Full text

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy

Anna Kreutzman, Vesa Juvonen, Veli Kairisto et al. · Blood · 2010 · 170 citations